ably desirable in view of the medical and economic conseinfluenza viruses. The remaining six internal genes were derived quences of this disease. An alternative to parenteral influenza from master cold-adapted strains (either type A or B) by the methimmunization is likely to be more readily accepted, particularly odology developed by Cox et al. [4] . CAIV-T (10 7 TCID 50 ) doses among children. Live, cold-adapted, attenuated, mucosally apretained at 020ЊC were reassayed for potency 1 month after the plied influenza vaccines (CAIVs) have been developed [1] and trial was completed in the spring of 1996 and were found to have found to be safe and immunogenic [2] . Although substantial monovalent and bivalent CAIVs [2, 3] , less is known about
Vaccine and placebo (allantoic fluid) were supplied by Aviron the safety and immunogenicity of trivalent CAIV (CAIV-T).
(Mountain View, CA). CAIV-T or placebo was administered intra-
The purpose of this study was to examine the safety, immunasally (0.5 mL, 0.25 mL in each nostril) as drops by a convennogenicity, and dose response of a CAIV-T administered to tional dropper calibrated at 0.25 and 0.5 mL (child supine) or by young children by either drops or spray.
using a spray device (child sitting). This spray device resembles a tuberculin syringe and produces a large-particle aerosol with an States, the randomization was also designed so that 50% of the cebo recipients were compared between each dose of CAIV-T and placebo recipients by x 2 or Fisher's exact test. Pre-and postvacciSimilarly, 118 children were enrolled in three stages (ratio of vaccine to placebo and dose escalation identical to the US sites) nation titers were converted to log 2 , and geometric mean titers were determined by calculating the anti-log of the mean log 2 titers. from one ambulatory clinic in the northern area of Santiago, Chile, between February and April 1996. However, Chilean children reFisher's exact test was used to compare the proportion of seroconversions among the 4 different dose groups (10 4 -10 7 TCID 50 ) for ceived vaccine or placebo as a spray only. Sixty children participated in stage 1, 30 in stage 2, and 28 in stage 3.
Methods
each individual strain. For all tests, statistical significance was declared if P £ .05. Note, because of the sequential assignment Children were eligible for the study if they were 18-71 months of age and in good health. Exclusion criteria included a history of of subjects to dose levels, the dose-response analyses do not account for the possibility that characteristics of participants (e.g., receiving any influenza vaccine, allergy to eggs, immunodeficiency in the subject or a household member, presence of a pregnant intercurrent infection, sex, age) may have changed over time. caretaker in the household, current upper respiratory infection, current febrile illness, current use of intranasal medication, receipt
Results
of blood products within 3 months before immunization, or wheezing or bronchodilator use within 1 year of enrollment. were compared with placebo recipients (table 1) . No serious the HAI titer of prevaccination serum was £1:4. Sera with a titer adverse events that were associated with CAIV-T were re-õ1:4 were assigned a titer of 1:2. Seroconversion to any of the antigens was defined as a §4-fold rise in antibody titer.
Participants. Study (CAIV-T and placebo) recipients had
ported. Also, there were no significant differences in rates of (122) 4 (3) 32 (26) 4 (3) 48 (39) 12 (10) 27 (22) 65 (53) NOTE. Data are no. (%) with adverse reaction. Seroconversion is defined as §4-fold rise in hemagglutination antibody inhibition titer before to after vaccination or a prevaccination titer of £1:4 and a postvaccination titer of 1: 8 to any strain. In United States, wild type H1N1 was circulating before postvaccination sera were obtained for 10 4 and 10 5 TCID 50 dosing phase and resulted in some antibody responses in these dosing groups. adverse reactions between CAIV-T and placebo recipients at Among children seronegative before vaccination, there were significant differences in the proportion of H3N2 and B seroany dose regardless of whether they received vaccine or placebo as drops or spray.
converters between the 10 4 and 10 5 -10 7 TCID 50 dose groups (P õ .001), with no significant differences noted between the Immunogenicity. Vaccine type -specific HAI seroconversion rates, postvaccination geometric mean titers, and the fold higher doses. For those seronegative to the H1N1 strain at baseline, the only significant difference in seroconversion rates rise in geometric mean titers before and after vaccination are shown in dose. Shedding of multiple vaccine virus types, particularly H3N2 and B, was common up to day 7 -10 after vaccination. Table 2 demonstrates that the seroconversion rates to the H3N2 and B strains were significantly higher than those of There were no significant differences in the proportion of children shedding vaccine virus between subjects who received placebo recipients for all CAIV-T doses except the H3N2 response for all subjects at the 10 4 TCID 50 dose. However, no CAIV-T by drops or by spray at any dose. H1N1 seroconversions were observed at any dose õ10 7 TCID 50 . While the proportion of subjects who seroconverted Discussion to the H1N1 strain was significantly higher for the 10 7 TCID 50 CAIV-T dose recipients (16% of seronegative subjects, 13%
This study demonstrated that CAIV-T was safe and welltolerated in children aged 18 -71 months, even at the highest overall) compared with placebo recipients, the rate of seroconversion may not be clinically relevant. There were no signifidose. Previous studies in adults and children have repeatedly demonstrated the safety of CAIVs [2] . cant differences in type-specific HAI responses at any dose among CAIV-T recipients who received drops or spray (data CAIV-T induced higher antibody responses to the H3N2 and B vaccine strains than to the H1N1 vaccine strain. Lower not shown).
seroconversion rates to at least one of the components of bivaresponses to all three vaccine antigens that are protective. A similar regimen is currently recommended for immunization lent or trivalent CAIVs in children have been previously reported [5 -7] . Differences in infectivity of multiple influenza of children receiving inactivated influenza vaccine for the first time. virus strains have also been observed in vitro and in mice [8] . Also, in the present study, the proportion of CAIV-T recipients who shed H3N2 and B vaccine viruses was higher than that
